These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 26540259)

  • 1. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
    Zinkernagel MS; Wolf S; Ebneter A
    Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.
    Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I
    Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study.
    Veritti D; Sarao V; Parravano M; Arias L; Varano M; Lanzetta P
    Eur J Ophthalmol; 2017 Jan; 27(1):74-79. PubMed ID: 27791249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion.
    Hoerster R; Muether PS; Sitnilska V; Kirchhof B; Fauser S
    Retina; 2014 Sep; 34(9):1767-73. PubMed ID: 24936942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration.
    Broadhead GK; Hong T; Zhu M; Li H; Schlub TE; Wijeyakumar W; Chang AA
    Retina; 2015 May; 35(5):975-81. PubMed ID: 25627086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of Pigment Epithelial Detachment to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration.
    Cho HJ; Kim KM; Kim HS; Lee DW; Kim CG; Kim JW
    Am J Ophthalmol; 2016 Jun; 166():112-119. PubMed ID: 27048998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
    Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
    Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
    de Massougnes S; Dirani A; Mantel I
    Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.
    Ricci F; Parravano M; Regine F; Sciamanna M; Tedeschi M; Missiroli F; Varano M
    Eye (Lond); 2016 Aug; 30(8):1077-83. PubMed ID: 27229701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months.
    Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
    Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.
    Major JC; Wykoff CC; Croft DE; Wang R; Mariani AF; Lehmann AE; Brown DM
    Can J Ophthalmol; 2015 Oct; 50(5):373-7. PubMed ID: 26455973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
    Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
    Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
    Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.